GeoVax Labs Inc
Veridion Score
Composite trend over time
Why is GOVX moving today?
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for GOVX.
GOVX insider activity
GeoVax Labs Inc
No multi-insider buying cluster in the last 90 days
Net buying: $6K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2025-10-20 | 2025-10-17 | SPENCER JOHN N JR | Insider | buy | $0.55 | 10,000 | 21,402 | $5K | SEC Form 4 |
| 2025-08-08 | 2025-08-07 | McKee Kelly T. Jr. | Insider | buy | $0.67 | 1,107 | 3,494 | $742 | SEC Form 4 |
GOVX contract awards, year to date.
Public federal awards linked to this ticker.
GOVX lobbying filings, year to date.
Registered lobbying filings matched to GeoVax Labs Inc.